228 THE SYNERGISTIC DRUG COMBINATION CRX-102 INHIBITS MATRIX METALLOPROTEINASE EXPRESSION IN MACROPHAGES AND HUMAN OSTEOARTHRITIC CHONDROCYTES  by Fraser, C.C. et al.
S106 Osteoarthritis and Cartilage Vol. 16 Supplement 4
226 HUMAN AMNIOTIC MEMBRANE TO REPAIR
OSTEOARTHRITIC CARTILAGE
S.M. Dı´az-Prado1, E. Muin˜os2, E. Rendal3, T. Hermida-Go´mez2,
I.M. Fuentes-Boquete1, M.C. Arufe-Gonda1, P. Filgueira4, M.J. Sa´nchez-
Dopico4, F.J. De Toro1, F. Galdo1, F.J. Blanco1. 1Osteoarticular and
Aging Research Laboratory. Biomedical Research Center. CIBER-BBN,
Cellular Therapy Area. INIBIC – Hospital Universitario Juan Canalejo.
University of A Corun˜a, Corun˜a, SPAIN, 2Osteoarticular and Aging
Research Laboratory. Biomedical Research Center. INIBIC-Hospital
Universitario Juan Canalejo., Corun˜a, SPAIN, 3CIBER-BBN, Cellular
Therapy Area., Corun˜a, SPAIN, 4Osteoarticular and Aging Research
Laboratory. Biomedical Research Center. CIBER-BBN, Cellular Therapy
Area. INIBIC – Hospital Universitario Juan Canalejo., Corun˜a, SPAIN
Purpose: Human amniotic membrane is a highly abundant and easily
accessible tissue that may potentially be an important chondrocyte carrier
for cartilage regeneration in vivo.
Objective: Study the feasibility of cryopreserved human amniotic mem-
brane as a chondrocyte carrier for in vitro repair human articular cartilage
injuries.
Methods: Patches (6×6 cm) of cryopreserved human amniotic mem-
brane were extended into a culture dish. Then human chondrocytes
(5×105 cells) were cultured over the basal face of the amniotic membrane
for 3−4 weeks until 80−90% conﬂuence. These membranes were cut into
pieces of 0.7×0.7 cm, and each of them was placed over a chondral
defect (6mm in diameter) of osteoarthritic cartilage with the basal layer
facing the defect. The implants were cultured for 16 weeks. Evaluation
of in vitro chondrocytes culture over the human amniotic membrane and
repair, in in vitro models, of injured articular cartilage was carried out us-
ing histological (hematoxylin-eosin) and immunohistochemical (collagen
type I and II) stainings.
Results: Chondrocytes culture over the human amniotic membrane
showed that cells grown over the basal layer, but they did not proliferate
on the epithelial side. Histological techniques demonstrated that collagen
type II but not type I was expressed in the chondrocytes culture on
amniotic membrane. Valuation of repair, in 13 in vitro repair models,
showed the formation of a new tissue on OA cartilage. Integration of new
tissue with OA cartilage was excellent. Repair tissue expressed type II
collagen in 100% of experiments, however collagen type I was present in
54% of cases.
Conclusions: These results indicated that cryopreserved amniotic mem-
brane can be used as support for chondrocytes proliferation in cell therapy
to repair OA cartilage.
Support: Project funded by Servizo Galego de Sau´de (PS07/84). Silvia
Diaz Prado is beneﬁciary of an Isidro Parga Pondal contract from Xunta
de Galicia, A Coruna, Spain.
227 GLUCOSAMINE PREVENTS AND NF-kB INHIBITORS
REDUCE THE CYTOKINE-INDUCED EXPRESSION OF Il-1 IN
NORMAL HUMAN ARTICULAR CHONDROCYTES IN VITRO
C.H. Lee, M. Glaysher, H.I. Roach. University of Southampton,
Southampton, UNITED KINGDOM
Purpose: Glucosamine (GlcN) supplements are taken by millions of
osteoarthritic (OA) patients to ameliorate their symptoms and several
large-scale studies have shown a beneﬁt in slowing the progression of
the disease. However, the molecular bases for the beneﬁcial effect of
GlcN are only beginning to be unravelled. Our aims were to determine
whether glucosamine, added to the medium of cultured non-OA chondro-
cytes, affected the cytokine-induced expression of Il-1b. In addition, we
investigated whether the NF-kB pathway is used in the signal transduction
mechanisms involved in the cytokine-induced expression of Il-1b.
Methods: Non-OA chondrocytes were isolated by sequential trypsin,
hyaluronidase and collagenase digestion from osteoporotic patients who
had sustained a fracture of the neck of femur. Previous studies had shown
that these chondrocytes are suitable control chondrocytes, because the
cells express chondrocytic genes, such as collagens types II, IX and
XI, but do not express Il-1b. Cells were maintained in MEM with 5%FCS.
Passage 2 cells were divided into the following experimental groups (n = 4
for each group): (I) control culture with no addition; (II) culture with GlcN
alone (2mM); (III) culture with TNF-a/OSM (10 ng/ml and 10m/ml) and
(IV) culture with TNF-a/OSM in presence of GlcN. In a further series,
non-OA chondrocytes were cultured with TNF-a/OSM in presence of two
compounds that inhibited the translocation of NF-kB to the nucleus. The
ﬁrst was NF-kB p65 (Ser 276) inhibitory peptide (50mM) from Imgenex,
the second was (E)-2-Fluoro-4’-methoxystilbene (0.2mM), an analogue
of Resveratrol from Merck. Media were changed twice-weekly, when the
relevant factors were also added to II, II and IV. Cells were cultured until
conﬂuency (2−3 weeks) and semi-quantitative RT-PCR was carried out.
Results: No expression of Il-1b was found in control cultures, with
GlcN alone or with the NF-kB inhibitor alone. As expected, TNF-a/OSM
induced expression of Il-1b in all cultures. However, the presence of
GlcN completed prevented the cytokine-induced expression of
Il-1b, as indicated by absence of the PCR band. Presence of the NF-
kB translocation inhibitors reduced Il-1b expression, but did not abolish it
completely, as suggested by reduced intensity of the PCR band.
Conclusions: The present studies demonstrate that glucosamine has
the capacity to inhibit the cytokine-induced expression of Il-1b. The
glucosamine effect was greater than the effect of interfering with the
NF-kB pathway of signal transduction. GlcN is a basic structural unit
of chondroitin sulphate and hyaluronan of cartilage proteoglycan aggre-
gates. Hence its beneﬁcial effects were initially suggested to be due to
stimulation of GAG synthesis, but the evidence for this mechanism is so
far limited. Other studies have shown chondroprotective effects in vitro
in that GlcN promoted the chondrogenic phenotype and inhibited MMP-
13 expression. Il-1b is thought to play a major role in the progression of
osteoarthritis, since Il-1b increases the expression of cartilage-degrading
proteases. The present study suggests that GlcN treatment may have
beneﬁcial effects through prevention of Il-1b expression, which, in turn,
might also reduce expression if its down-stream target genes. However,
these are in vitro observations and need to be conﬁrmed by in vivo
studies.
228 THE SYNERGISTIC DRUG COMBINATION CRX-102
INHIBITS MATRIX METALLOPROTEINASE EXPRESSION
IN MACROPHAGES AND HUMAN OSTEOARTHRITIC
CHONDROCYTES
C.C. Fraser1, Y. Wang1, J. Lehar1, E. Lee2, K. McCabe2, S. O’Brien2,
S. Kilfeather2, A. Borisy1, G.R. Zimmermann1. 1CombinatoRx
Pharmaceuticals, Cambridge, MA, USA, 2Aeirtec Ltd, Newcastle Upon
Tyne, UNITED KINGDOM
Purpose: Glucocorticoids are therapeutic anti-inﬂammatory drugs, but
are not routinely used to treat osteoarthritis (OA) due to potential side
effects. In a proof-of-concept hand OA clinical trial, oral dosing with CRx-
102, which is a combination of the cardiovascular drug dipyridamole (Dp)
and very low-dose prednisolone (Pd), resulted in a signiﬁcant reduction
in tender and swollen joint counts, suggesting that the combination
may modify disease progression. We have previously shown that Dp
synergizes with Pd to inhibit inﬂammation in vitro and in vivo. This synergy
allows a much lower dose of Pd to be used to inhibit inﬂammation, without
the side effects associated with glucocorticoids. To determine if Dp and
Pd synergize to inhibit matrix metalloproteinase (MMP) expression, we
studied LPS-stimulated macrophages and Il-1a stimulated normal human
chondrocytes. Additionally, we evaluated the activity of the combination
on chondrocytes from human osteoarthritic joints ex vivo. The purpose
of this research was to characterize the effect of the combination of Dp
and Pd on cells and molecules relevant to the progression of OA.
Methods and Results: Transcriptional proﬁling (TP) of LPS stimulated
macrophages revealed that ADAMTS4 was up-regulated (~20-fold) in
response to LPS. Dp (10 uM) in combination with Pd (0.03 uM) inhibited
ADAMTS4 expression (67%), more than Dp (47%) or Pd (30%) alone.
MMPs 3, 10, 12, 13 and 14 were up-regulated in response to LPS, and
like ADAMTS4, were maximally inhibited by the combination of Dp and
Pd. Interestingly, analysis of supernatants from stimulated macrophages
cultured in serially diluted combinations of Pd and Dp identiﬁed strong
synergistic inhibition of MMP2 and MMP9. The MAP kinase pathway is
thought to play a role in MMP expression. Western blot analysis showed
the combination of Pd and Dp inhibited phosphorylation of p38 and JNK
but not ERK, while Pd or Dp alone did not. To further characterize the
combination on OA-relevant cell types, inhibition of MMPs and other
inﬂammatory mediators by Dp and Pd was measured in Il-1a stimulated
primary chondrocytes from normal human donors. Pd demonstrated
differential partial inhibition of MMP-3, Il-6, MCP-1 and GRO-alpha. Dp
demonstrated complete inhibition of MMP-3 and MCP-1, partial inhibition
of GRO-alpha, and no inhibition of Il-6. OA chondrocytes were isolated
from osteoarthritic joint cartilage obtained from total knee replacement
surgery, and the ability of Dp and Pd to suppress Il-1 induced production
of pro-inﬂammatory mediators including MMPs was assessed. Dp and
Pd alone and in combination suppressed production of TNFa, MIP-1a,
MIP-1b, MCP-1, RANTES, and MMP-13.
Conclusions: We show here that Pd and Dp synergize to inhibit
MMP production in macrophages and decrease expression in human
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osteoarthritis-derived chondrocytes ex vivo. The synergy between Pd
and Dp allows a very low dose of Pd to be used clinically, potentially
overcoming many glucocorticoid-related side effects. The combination
(CRx-102) has demonstrated efﬁcacy in a Phase 2a hand OA trial and in a
Phase 2a rheumatoid arthritis trial. The broad anti-inﬂammatory synergy
of Dp and Pd, and the ability to inhibit MMPs may contribute to clinical
efﬁcacy, supporting the notion that the sensitization to glucocorticoids by
dipyridamole may alter disease progression in OA.
229 UP-REGULATED EXPRESSION OF ANK IN JOINT TISSUE
FROM PATIENTS WITH CALCIUM PYROPHOSPHATE
DIHYDRATE CRYSTAL DEPOSITION DISEASE (CPPD)
M. Uzuki1, L.M. Ryan2, T. Sawai1, I. Masuda2. 1Iwate Medical University,
School of Medicine, Morioka, Iwate, JAPAN, 2Medical College of
Wisconsin, Milwaukee, WI, USA
Purpose: Extracellular inorganic pyrophosphate (ePPi) promotes CPPD
crystal formation in cartilage matrix in patients with osteoarthritis. ANK
was recently proposed to be an important factor in transport of intracel-
lular inorganic pyrophosphate (iPPi) across the cell membrane. The ANK
protein is a multiple transmembrane protein either serving as an anion
channel or as a regulator of such a channel. In this study, we examined
the expression of ANK in the joint tissue of patients with CPPD to study
its possible biological roles in the manifestation of this disorder.
Methods: Cartilage, meniscus and synovial tissues used in this study
were obtained from 15 patients with osteoarthritis with CPPD crystals
(CPPD), 10 patients with osteoarthritis without crystal (OA) and 2 normal
from autopsy cases. We studied the expression of ANK in joint tissue
using immunohistochemistory. As a negative control, non-immune rabbit
IgG was used instead of primary antibody for ANK. We counted the
number of ANK positive cells in the joint tissues.
Results: ANK immunoreactivity was detected in synovial cells, chon-
drocytes and matrix of cartilage and meniscus. The numbers of ANK
positive cells in the joint tissues was signiﬁcantly higher in CPPD than
in OA or normal (Fig. 1: cartilage, Fig. 2: meniscus, Fig. 3: synovium).
The immunoreactivities reached maximum levels in hypertrophic chondro-
cytes around the deposits of crystals, both in their number and intensity,
especially in their cell membranes.
Conclusions: ANK was seen in the joint tissue of patients with CPPD,
especially around the deposits of crystals. These ﬁndings suggest that up-
regulated ANK experession contributes to CPPD crystal forming cartilage.
ANK may control iPPi egress across the cell membrane.
Figure 1.
Figure 2.
Figure 3.
230 LEPTIN ENHANCES MMP-1, MMP-3 AND MMP-13
PRODUCTION IN HUMAN OA CARTILAGE
K. Vuolteenaho1, A. Koskinen1, R. Nieminen1, T. Moilanen2,
E. Moilanen1. 1The Immunopharmacology Research Group, Medical
School, University of Tampere and Tampere University Hospital,
Tampere, FINLAND, 2Coxa Hospital for Joint Replacement and The
Immunopharmacology Research Group, Medical School, University of
Tampere, Tampere, FINLAND
Purpose: Obesity is an important risk factor for OA of weight-bearing
joints, but also for hand joints, pointing to an obesity-related metabolic fac-
tor that inﬂuences on the susceptibility or pathogenesis of OA. Leptin is a
proinﬂammatory adipokine regulating energy balance and it has recently
been related also to arthritis and cartilage metabolism. In OA, proteolytic
degradation of cartilage is mediated by matrix metalloproteinases. In the
present study, the effects of leptin on MMP-1, MMP-3, MMP-8 and MMP-
13 production in human OA cartilage were studied.
Methods: Cartilage tissue obtained from the leftover pieces of total knee
replacement surgery from patients with OA was used in the experiments.
MMP production in the culture medium was measured by multiplex bead
array method (Luminex).
Results: Leptin alone and in combination with Il-1 enhanced production
of collagenases MMP-1 and MMP-13, and stromelysin-1 (MMP-3) in
human OA cartilage, while collagenase-2 (MMP-8) concentrations re-
mained undetectable. The effects of leptin on MMP-1, MMP-3 and MMP-
13 production were mediated through transcription factor NF-úB, and
through PKC and MAP kinase JNK. In addition, p38 pathway was involved
in the leptin-induced MMP-1 and MMP-13 production and Erk1/2 pathway
in MMP-1 production.
Conclusions: The ﬁndings support the idea of leptin as a detrimental
factor in OA cartilage and as a link between obesity and increased risk
for osteoarthritis.
231 ROLE OF SP1 TRANSCRIPTION FACTOR IN INTERLEUKIN-1
INDUCED ADAMTS-4 GENE EXPRESSION IN HUMAN
ARTICULAR CHONDROCYTES
J. Sylvester, R. Ahmad, M. Zafarullah. University of Montreal, Montreal,
QC, CANADA
Purpose: Proinﬂammatory cytokines such as interleukin-1 beta (Il-1b)
stimulate cartilage extracellular matrix aggrecan degradation by ag-
grecanases or ADAMTS (a disintegrin and metalloproteinase with
thrombospondin-like motif). Human aggrecanase-1 (ADAMTS-4) gene
promoter contains one speciﬁcity protein-1 (Sp1)-transcription factor-
binding site. We investigated the previously unknown role of Sp1 in the
regulation of ADAMTS-4 gene expression.
Methods: Normal human knee chondrocytes were grown in Differentia-
tion Bullekit medium as high-density short-term monolayer cultures. Cells
were either treated with various pharmacological inhibitors or transfected
with senase and antisense Sp1 oligonucleotides as well as negative
control or Sp1-speciﬁc siRNAs. Subsequently, cells were stimulated with
Il-1b. Knockdown of respective proteins and effect on aggrecanase-1 was
studied by RT-PCR and Western blot analysis.
Results: Mithramycin and WP631, the speciﬁc inhibitors of guanine
cytosine-rich SP1 DNA binding partially suppressed Il-1-induced ex-
pression of ADAMTS-4. Genetic inhibition of Sp1 by transfection of
antisense oligonucleotide or Sp1 knockdown by RNA interference with
small interfering RNA (siRNA) partially inhibited ADAMTS-4 induction by
Il-1. Sense oligonucleotide and negative control siRNA had no effect.
